1. Rubin EH, Gilliland DG. Drug development and clinical trials-the path to an approved cancer drug. Nature reviews. Clin Oncol. 2012;9:215–222.
2. Burns DK. Developing pharmacogenetic evidence throughout clinical development. Clin Pharmacol Ther. 2010;88:867–870.
3. Yang L, Rieves D, Ganley C. Brain amyloid imaging-FDA approval of florbetapir F18 injection. N Engl J Med. 2012;367:885–887.
4. US Food and Drug Administration. Guidance for industry: developing medical imaging drug and biological products. Part 1: conducting safety assessments. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078930.pdf. Accessed October 15, 2013.
5. US Food and Drug Administration. Guidance for industry: developing medical imaging drug and biological products. Part 2: clinical indications. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071603.pdf. Accessed October 15, 2013.